Cushing's syndrome
Endocrinology · 2023–2024
2decisions
1medicine
1carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| osilodrostat Treatment of endogenous Cushing's syndrome in adults who are not candidates for surgery or for whom surgery was not curative. | Sep 2024 | Recommended with restriction | unclear |
| osilodrostat Treatment of adult patients with endogenous Cushing's syndrome who are not candidates for surgery or for whom surgery was not curative. | Mar 2023 | Not recommended | 2 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.